Equities

Canopy Growth Corp

Canopy Growth Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)5.27
  • Today's Change-0.255 / -4.62%
  • Shares traded1.85m
  • 1 Year change-27.88%
  • Beta1.7682
Data delayed at least 15 minutes, as of Nov 14 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.

  • Revenue in CAD (TTM)280.50m
  • Net income in CAD-585.69m
  • Incorporated2009
  • Employees1.03k
  • Location
    Canopy Growth Corp1 Hershey DrSMITHS FALLS K7A 0A8CanadaCAN
  • Phone+1 (613) 599-9600
  • Fax+1 (613) 599-0018
  • Websitehttps://www.canopygrowth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Spectral Medical Inc2.01m-25.08m152.72m29.00------76.13-0.0895-0.08960.0072-0.11060.23693.883.8069,172.41-296.18-109.65---175.3539.7863.74-1,250.20-445.720.2057-1.22-----4.14-16.08-104.12--31.53--
Cipher Pharmaceuticals Inc37.03m22.19m325.23m9.0014.412.3512.478.780.8820.8821.485.410.21661.302.664,114,980.0012.9821.5314.6027.4080.7883.5859.9257.311.64--0.29190.002.36-1.44-23.4876.18-53.51--
Aurora Cannabis Inc296.39m-29.03m349.02m1.07k--0.6424--1.18-0.6063-0.87495.779.900.36431.697.42276,222.80-3.94---4.87---0.0165---10.81--1.88--0.1476--------------
Knight Therapeutics Inc348.64m-30.73m520.03m725.00--0.67226.171.49-0.2979-0.29793.427.660.35331.594.02480,878.60-3.110.3477-3.530.415648.2646.28-8.811.692.390.23850.070.0011.8092.2443.68--20.79--
Canopy Growth Corp280.50m-585.69m663.09m1.03k--1.02--2.36-6.98-6.733.325.430.19342.176.16272,590.90-40.38-26.08-48.35-28.6731.472.59-208.81-333.291.07-0.29730.5462---10.835.5984.29---64.60--
Cronos Group Inc155.68m-66.57m1.16bn626.00--0.7652--7.44-0.175-0.17450.40683.960.09532.286.14---4.206.43-4.437.1114.66-10.54-44.12147.0723.05--0.00--0.567248.4054.99---50.99--
Data as of Nov 14 2024. Currency figures normalised to Canopy Growth Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.